Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron’s (REGN) opportunity for Q2 upside is “substantial.” Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug’s first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations “this quarter and beyond.” The analyst maintains an Overweight rating on Regeneron with a $450 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.